Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of Entrada Therapeutics (NASDAQ:TRDA - Free Report) from a hold rating to a sell rating in a research note released on Saturday morning.

Separately, HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Tuesday, May 20th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $25.67.

Entrada Therapeutics Price Performance

Shares of Entrada Therapeutics stock traded down $0.20 during trading on Friday, hitting $7.21. The company's stock had a trading volume of 127,210 shares, compared to its average volume of 133,286. The stock has a market cap of $273.62 million, a price-to-earnings ratio of 8.90 and a beta of -0.06. Entrada Therapeutics has a 52 week low of $7.10 and a 52 week high of $21.79. The stock has a 50-day moving average price of $8.19 and a two-hundred day moving average price of $11.75.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.36. Entrada Therapeutics had a return on equity of 5.84% and a net margin of 14.39%. The firm had revenue of $8.75 million for the quarter, compared to analyst estimates of $10.98 million. On average, equities analysts predict that Entrada Therapeutics will post 1.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TRDA. Charles Schwab Investment Management Inc. boosted its position in shares of Entrada Therapeutics by 6.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 197,127 shares of the company's stock valued at $3,408,000 after purchasing an additional 11,143 shares in the last quarter. AlphaQuest LLC bought a new position in shares of Entrada Therapeutics during the 4th quarter worth approximately $70,000. American Century Companies Inc. boosted its holdings in shares of Entrada Therapeutics by 17.7% during the 4th quarter. American Century Companies Inc. now owns 59,710 shares of the company's stock worth $1,032,000 after buying an additional 8,985 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Entrada Therapeutics during the 4th quarter worth approximately $36,000. Finally, LPL Financial LLC increased its stake in shares of Entrada Therapeutics by 12.9% in the 4th quarter. LPL Financial LLC now owns 55,154 shares of the company's stock valued at $954,000 after acquiring an additional 6,310 shares in the last quarter. 86.39% of the stock is owned by institutional investors.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.